

12/24/2003
700058280

Form PTO-1594 (Rev. 03/01) OMB No. 0651-0027 (exp. 5/31/2002) **RECORDATION FORM COVER SHEET TRADEMARKS ONLY** U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):
Sagres Discovery Inc.
 Individual(s) Association
 General Partnership Limited Partnership
 Corporation-State Delaware
 Other:
Additional name(s) of conveying party(ies) attached? Yes No

2. Name and address of receiving party(ies):
Name: Forward Ventures IV, L.P.
Internal Address:
Street Address: 9393 Towne Centre Drive Suite 200
City: San Diego
State: CA Zip: 92121
 Individual(s) citizenship:
 Association:
 General Partnership:
 Limited Partnership: Delaware
 Corporation-State:
 Other:
If assignee is not domiciled in the United States, a domestic representative designation is attached: Yes No
Additional name(s) & address(es) attached? Yes No
See Attachment A

3. Nature of Conveyance:
 Assignment Merger
 Security Agreement Change of Name
 Other:
Execution Date: December 19, 2003

4. Application Number(s) or Registration Number(s):
A. Trademark Application No.(s):
See Attachment B
Additional numbers attached? Yes No

B. Trademark Registration No.(s):
See Attachment B
Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:
Name: Bruce D. Grant
MORRISON & FOERSTER LLP
Internal Address: Atty. Dkt.: 555610000001
Street Address: 3811 Valley Centre Drive, Suite 500
City: San Diego State: CA Zip: 92130-2332

6. Total Number of applications and registrations involved: 11
7. Total fee (37 CFR 3.41) \$ 290.00
 Enclosed
 Authorized to be charged to Deposit Account
 Authorized to be charged to credit card (Form 2038 enclosed)
8. Deposit account number: 03-195 referencing 555610000001
(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature:
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.
for Bruce D. Grant
Name of Person Signing
Signature: *[Signature]*
Date: December 24, 2003
Total number of pages including cover sheet, attachments, and document: 24

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, Assignment Services Division, facsimile no. (703) 306-5995, on the date shown below.
Dated: 12-24-03 Signature: *[Signature]* (Michael Boyd)

ATTACHMENT A TO RECORDATION FORM COVER SHEET

ADDITIONAL RECEIVING PARTIES

Forward Ventures IV B, L.P.
9393 Towne Centre Drive, Suite 200
San Diego, CA 92121

Axiom Venture Partners
185 Asylum Street, 17th Floor
Hartford, CT 06103

Blue Dot Capital PTE Ltd.
51 Cuppage Road
#09-01 StarHub Centre
Singapore 229469

Burrill Biotechnology Capital Fund, L.P.
One Embarcadero Center, Suite 2700
San Francisco, CA 94111

JAFCO G-8 (A) Investment Enterprise Partnership
Tekko Bldg., 1-8-2, Marunouchi
Chiyoda-ku, Tokyo 100-0005
Japan

JAFCO G-8 (B) Investment Enterprise Partnership
Tekko Bldg., 1-8-2, Marunouchi
Chiyoda-ku, Tokyo 100-0005
Japan

JAFCO G-C-1 Investment Enterprise Partnership
Tekko Bldg., 1-8-2, Marunouchi
Chiyoda-ku, Tokyo 100-0005
Japan

Lotus Bioscience Investment Holdings Ltd.
c/o 9/F, Central Building
3 Pedder Street, Central
Hong Kong

Novartis Bioventures, Ltd.
Hurst Holme, 12 Trott Road
P.O. Box HM 2899
Hamilton Bermuda, HM LX

ATTACHMENT B TO THE RECORDATION FORM COVER SHEET

REGISTRATION SERIAL No.	TRADEMARK	JURISDICTION REGISTERED	REGISTRATION DATE
76267959	Oncogenome	United States	Published 10/1/02
76267958	Oncogenome	United States	Published 10/22/02
76316787	Oncoarray	United States	Published 2/26/02
76335326	Making Sense of the Genome	United States	Misassigned 1/3/02
2627681	Sagres Discovery	United States	10/1/02
76307745	Oncochip	United States	Published 1/7/03
76226665	Sagres	United States	Published 7/9/02
76358674	Making Sense of the Genome	United States	Filed 1/10/02
78228632	Oncobank	United States	Filed 3/21/03
2741602	Making Sense of the Oncogenome	United States	7/29/03
2694913	GATC	United States	3/11/03

PATENT AND TRADEMARK SECURITY AGREEMENT

THIS PATENT AND TRADEMARK SECURITY AGREEMENT (this "Agreement"), dated as of December 19, 2003, is made between Sagres Discovery, Inc., a Delaware corporation ("Grantor"), and the parties (each a "Secured Party" and, collectively, the "Secured Parties") named on the signature pages hereto.

Grantor and Secured Parties hereby agree as follows:

Section 1. Definitions; Interpretation.

(a) Terms Defined in Security Agreement. All capitalized terms used in this Agreement and not otherwise defined herein shall have the meanings assigned to them in the Security Agreement.

(b) Certain Defined Terms. As used in this Agreement, the following terms shall have the following meanings:

"Collateral" has the meaning set forth in Section 2.

"PTO" means the United States Patent and Trademark Office.

"Security Agreement" means the Security Agreement dated as of December 15, 2003 between Grantor and Secured Parties.

(c) Terms Defined in UCC. Where applicable and except as otherwise defined herein, terms used in this Agreement shall have the meanings assigned to them in the UCC.

(d) Interpretation. The rules of interpretation applicable to the Security Agreement shall also be applicable to this Agreement and are incorporated herein by this reference.

Section 2. Security Interest.

(a) Grant of Security Interest. As security for the payment and performance of the Obligations, including interest that accrues after the commencement by or against Grantor of any bankruptcy or insolvency proceeding naming such Person as the debtor in such proceeding, Grantor hereby assigns, transfers and conveys to Secured Parties, and grants a security interest in and mortgage to Secured Parties, all of Grantor's right, title and interest in, to and under the following property, in each case whether now or hereafter existing or arising or in which Grantor now has or hereafter owns, acquires or develops an interest and wherever located (collectively, the "Collateral"):

(i) all patents and patent applications, domestic or foreign, all licenses relating to any of the foregoing and all income and royalties with respect to any licenses (including such patents and patent applications as described in Schedule A), all rights to sue for past, present or future infringement thereof, all rights arising therefrom and pertaining thereto and all reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof;

1.

(ii) all state (including common law), federal and foreign trademarks, service marks and trade names, and applications for registration of such trademarks, service marks and trade names, all licenses relating to any of the foregoing and all income and royalties with respect to any licenses (including such marks, names and applications as described in Schedule B), whether registered or unregistered and wherever registered, all rights to sue for past, present or future infringement or unconsented use thereof, all rights arising therefrom and pertaining thereto and all reissues, extensions and renewals thereof;

(iii) the entire goodwill of or associated with the businesses now or hereafter conducted by Grantor connected with and symbolized by any of the aforementioned properties and assets;

(iv) all commercial tort claims associated with or arising out of any of the aforementioned properties and assets;

(v) all accounts, all intangible intellectual or other similar property and other general intangibles associated with or arising out of any of the aforementioned properties and assets and not otherwise described above, including all license payments and payments under insurance (whether or not any Secured Party or any Collateral Agent is the loss payee thereof) or any indemnity, warranty or guaranty payable by reason of loss or damage to or otherwise with respect to the foregoing Collateral; and

(vi) all products, proceeds and supporting obligations of or with respect to any and all of the foregoing Collateral.

(b) Continuing Security Interest. Grantor agrees that this Agreement shall create a continuing security interest in the Collateral which shall remain in effect until terminated in accordance with Section 12.

(c) Pari Passu Interests in the Collateral. Each Secured Party's interest in the Collateral shall be on a parity with the interests of all other Secured Parties, and the interest of each Secured Party in the Collateral shall be ratable in the proportion that the aggregate indebtedness then outstanding and unpaid under the Notes held by such Secured Party bears to the aggregate indebtedness then outstanding and unpaid under the Notes held by all Secured Parties.

Section 3. Supplement to Security Agreement. This Agreement has been granted in conjunction with the security interests granted to Secured Parties under the Security Agreement. The rights and remedies of Secured Parties and any Collateral Agent with respect to the security interests granted herein are without prejudice to, and are in addition to those set forth in the Security Agreement, all terms and provisions of which are incorporated herein by reference.

Section 4. Representations and Warranties. Grantor represents and warrants to Secured Parties that:

(a) Patents. A true and correct list of all of the existing Collateral consisting of U.S. patents and patent applications and/or registrations owned by Grantor, in whole or in part, is set forth in Schedule A.

(b) Trademarks. A true and correct list of all of the existing Collateral consisting of U.S. trademarks, trademark registrations and/or applications owned by Grantor, in whole or in part, is set forth in Schedule B.

Section 5. Further Acts. On a continuing basis, Grantor shall make, execute, acknowledge and deliver, and file and record in the proper filing and recording places, all such instruments and documents, and take all such action as may be necessary or advisable or may be requested by any Secured Party or any Collateral Agent to carry out the intent and purposes of this Agreement, or for assuring, confirming or protecting the grant or perfection of the security interest granted or purported to be granted hereby, to ensure Grantor's compliance with this Agreement or to enable any Secured Party or any Collateral Agent to exercise and enforce its rights and remedies hereunder with respect to the Collateral, including any documents for filing with the PTO and/or any applicable state office. Any Secured Party or any Collateral Agent may record this Agreement, an abstract thereof, or any other document describing Secured Parties' interest in the Collateral with the PTO, at the expense of Grantor.

Section 6. Authorization to Supplement. If Grantor shall obtain rights to any new trademarks, any new patentable inventions or become entitled to the benefit of any patent application or patent for any reissue, division, or continuation, of any patent, the provisions of this Agreement shall automatically apply thereto. Grantor shall give prompt notice in writing to each Secured Party and any Collateral Agent with respect to any such new trademarks or patents, or renewal or extension of any trademark registration. Without limiting Grantor's obligations under this Section 6, Grantor authorizes any Secured Party or any Collateral Agent to modify this Agreement by amending Schedules A or B to include any such new patent or trademark rights. Notwithstanding the foregoing, no failure to so modify this Agreement or amend Schedules A or B shall in any way affect, invalidate or detract from Secured Parties' continuing security interest in all Collateral, whether or not listed on Schedule A or B.

Section 7. Binding Effect. This Agreement shall be binding upon, inure to the benefit of and be enforceable by Grantor, Secured Parties and their respective successors and assigns and shall bind any Person who becomes bound as a debtor to this Agreement. Any Collateral Agent is expressly designated as a third party beneficiary hereof, and this Agreement shall also inure to the benefit of any Collateral Agent. Grantor may not assign, transfer, hypothecate or otherwise convey its rights, benefits, obligations or duties hereunder except as specifically permitted by the Security Agreement.

Section 8. Notices. All notices or other communications hereunder shall be in writing (including by facsimile transmission or by email) and mailed, sent or delivered to the respective parties hereto (in the case of Grantor) at or to its address, facsimile number or email address set forth below on the signature pages hereof or (in the case of the Secured Parties) at or to their respective addresses, facsimile numbers or email addresses set forth in the Security Agreement, or at or to such other address, facsimile number or email address as shall be designated by any party in a written notice to the other parties hereto. All such notices and other communications shall be deemed to be delivered when a record (within the meaning of the UCC) has been (i) delivered by hand; (ii) sent by mail upon the earlier of the date of receipt or five business days after deposit in the mail, first class (or air mail as to communications sent to or from the United States); (iii) sent by facsimile transmission; or (iv) sent by email.

Section 9. Governing Law. This Agreement shall be governed by, and construed in accordance with, the law of the State of California, except as required by mandatory provisions of law and to the extent the validity or perfection of the security interests hereunder, or the remedies hereunder, in respect of any Collateral are governed by the law of a jurisdiction other than California.

Section 10. Amendment; Conflict. Except as provided in Section 1.2 of the Purchase Agreement, no amendment to this Agreement, or any waiver of any provision hereof, shall be effective unless it is in writing and signed by the Majority Secured Parties and (in the case of any amendment) the Debtor; provided, however, that without the consent of all Secured Parties, no amendment, waiver or consent shall do any of the following: (i) change the definition of "Majority Secured Parties" or any definition or provision of this Agreement requiring the approval of the Secured Parties or some other specified amount of Secured Parties; or (ii) amend the provisions of this Section 10; and provided, further, that no amendment, waiver or consent shall, unless in writing and signed by the Collateral Agent, affect the rights, duties or obligations of the Collateral Agent under or in respect of this Agreement. To the extent that any provision of this Agreement conflicts with any provision of the Security Agreement, the provision giving Secured Parties greater rights or remedies shall govern, it being understood that the purpose of this Agreement is to add to, and not detract from, the rights granted to Secured Parties under the Security Agreement.

Section 11. Counterparts. This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts and by facsimile, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute but one and the same agreement.


Section 12. Termination. Upon payment and performance in full of all Obligations, the security interests created by this Agreement, and all representations, warranties and covenants of Debtor contained herein, shall terminate and Secured Parties shall promptly execute and deliver to Grantor such documents and instruments reasonably requested by Grantor as shall be necessary to evidence termination of all such security interests given by Grantor to Secured Parties hereunder, including cancellation of the security interests created by this Agreement by written notice from Secured Parties to the PTO.

[Signature pages to follow]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement,
as of the date first above written.

GRANTOR

Sagres Discovery, Inc.

By: 

Name: Michael Miille, Ph.D.
Title: Chief Financial Officer

Address:

3795 Second Street, Suite 400

Davis, CA 95616

Attn: Michael Miille

Fax: (530) 297-4701

Email: mjmiille@sagresdiscovery.com

IT BY: SAGRES DISCOVERY; 530 297 4701; DEC-16-03 5:34PM; PAGE 2
DEC-16-03 16:19 FROM-FORWARD VENTURES +8588645029 T-567 P-002/006 F-973

SECURED PARTIES:

FORWARD VENTURES IV, L.P.

By: Forward IV Associates, LLC

Its: General Partner

By: 

Ivor Royston, MD,
Managing Member

Address:

9393 Towne Centre Drive, Suite 200
San Diego, CA 92121

Facsimile: (858) 677-6077

Domicile of Secured Party (CA, DE, other):

CA


Type of entity (corporation, general partnership,
limited partnership, other):

Limited Partnership

SENT BY: SAGRES DISCOVERY; 530 297 4701; DEC-16-03 5:34PM; PAGE 3
DEC-16-03 15:13 FROM-FORWARD VENTURES +85806646028 T-563 P.003/006 F-473

FORWARD VENTURES IV B, L.P.

By: Forward IV Associates, LLC
Its: General Partner

By: 

Ivor Royston, MD,
Managing Member


Address:
9393 Towne Centre Drive, Suite 200
San Diego, CA 92121

Facsimile: (858) 677-6077

Domicile of Secured Party (CA, DE, other):
CA

Type of entity (corporation, general partnership,
limited partnership, other):
Limited Partnership

AXIOM VENTURE PARTNERS

By: 
Name: MARC FOGASSA
Title: PRINCIPAL

Address: 165 ASYLUM ST - 17TH FLOOR
HARTFORD, CT 06103

Facsimile: (860) 548-7797

Domicile of Secured Party (CA, DE, other):
CT

Type of entity (corporation, general partnership,
limited partnership, other):
GENERAL PARTNERSHIP

BLUE DOT CAPITAL PTE LTD

By: *Boon Swan Foo*
Boon Swan Foo

Address: 51 Cuppage Road, #09-01 StarHub Centre
Singapore 229469

Facsimile: (65) 67202281

Domicile of Secured Party (CA, DE, other):
Singapore

Type of entity (corporation, general partnership,
limited partnership, other):
Private Limited Company

sd-175861
437786 y1/AN
9DSQ011DOC

[SIGNATURE PAGE TO THE
SAGRES DISCOVERY, INC PATENT AND TRADEMARK SECURITY AGREEMENT]

BURRILL BIOTECHNOLOGY CAPITAL FUND, L.P.

By: *[Signature]*

Name: G. Steven Burrill

Title: CEO, Burrill or Company, its General Partner


Address: One Embarcadero City, Ste 2700
San Francisco, CA 94111

Facsimile: (415) 591-5401

Domicile of Secured Party (CA, DE, other):
DE entity

Type of entity (corporation, general partnership, limited partnership, other):
Limited Partnership

**JAFCO G-8 (A) INVESTMENT ENTERPRISE
PARTNERSHIP**

By: 
Tomio Kezuka
Executive Vice President, JAFCO Co., Ltd,
Its Executive Partner

Address: Tekko Bldg., 1-8-2, Marunouchi,
Chiyoda-ku, Tokyo 100-0005
Japan

Facsimile: +81-3-5223-7095

Domicile of Secured Party (CA, DE, other):
Tokyo, Japan

Type of entity (corporation, general partnership,
limited partnership, other):
Partnership under Japanese civil law

**JAFCO G-8 (B) INVESTMENT ENTERPRISE
PARTNERSHIP**

By: *Tomio Kezuka*
Tomio Kezuka
Executive Vice President, JAFCO Co., Ltd,
Its Executive Partner

Address: Tekko Bldg., 1-8-2, Marunouchi,
Chiyoda-ku, Tokyo 100-0005
Japan

Facsimile: +81-3-5223-7095

Domicile of Secured Party (CA, DE, other):
Tokyo, Japan

Type of entity (corporation, general partnership,
limited partnership, other):
Partnership under Japanese civil law

**JAFCO G-C-1 INVESTMENT ENTERPRISE
PARTNERSHIP**

By: *Tomio Kezuka*
Tomio Kezuka
Executive President, JAFCO Co., Ltd,
Its Executive Partner


Address: Tekko Bldg., 1-8-2, Marunouchi,
Chiyoda-ku, Tokyo 100-0005
Japan

Facsimile: +81-3-5223-7095

Domicile of Secured Party (CA, DE, other):
Tokyo, Japan

Type of entity (corporation, general partnership,
limited partnership, other):
Partnership under Japanese civil law

**LOTUS BIOSCIENCE INVESTMENT
HOLDINGS LTD.**

By: 
Mong Cheuk Wai & Wong Ken Lum
Directors

Address: c/o 9/F, Central Building,
3 Pedder Street, Central
Hong Kong

Facsimile: 852-2524 1276

Domicile of Secured Party (CA, DE, other):

Type of entity (corporation, general partnership,
limited partnership, other):

Corporation

NOVARTIS/BIOVENTURES, LTD.

By: Emil Bock

Name: Emil Bock

Title: Member of the Board of Directors

Address:

Hurst Holme, 12 Trott Rd.

P.O. Box HM 2899

Hamilton Bermuda, HM LX

Facsimile: 001 441 296 5083

Domicile of Secured Party (CA, DE, other):

Bermuda

Type of entity (corporation, general partnership,
limited partnership, other):

Corporation

SCHEDULE A
to the Patent and Trademark Security Agreement
Issued U.S. Patents of Grantor

NONE

Pending U.S. Patent Applications of Grantor

COUNTRY	TITLE	APPLICATION NUMBER	OWNER
US	NOVEL COMPOSITIONS AND METHODS FOR BREAST CANCER	10/035,832	SAGRES DISCOVERY, INC.
US	NOVEL COMPOSITIONS AND METHODS FOR CANCER	10/085,117	SAGRES DISCOVERY, INC.
US	NOVEL COMPOSITIONS AND METHODS FOR CANCER	10/087,192	SAGRES DISCOVERY, INC.
US	NOVEL COMPOSITIONS AND METHODS FOR CANCER	09/997,722	SAGRES DISCOVERY, INC.
US	NOVEL COMPOSITIONS AND METHODS IN CANCER ASSOCIATED WITH ALTERED EXPRESSION OF MCM3AP	10/105,612	SAGRES DISCOVERY, INC.
US	NOVEL COMPOSITIONS AND METHODS FOR CANCER	10/004,113	SAGRES DISCOVERY, INC.
US	NOVEL COMPOSITIONS AND METHODS FOR CANCER	10/034,650	SAGRES DISCOVERY, INC.
US	NOVEL COMPOSITIONS AND METHODS IN CANCER ASSOCIATED WITH ALTERED EXPRESSION OF KCNJ9	10/105,871	SAGRES DISCOVERY, INC.
WO	NOVEL COMPOSITIONS AND METHODS FOR CANCER	PCT/US02/33835	SAGRES DISCOVERY, INC.
WO	NOVEL COMPOSITIONS AND METHODS FOR CANCER	PCT/US02/36071	SAGRES DISCOVERY, INC.
WO	NOVEL COMPOSITIONS AND METHODS FOR CANCER	PCT/US02/38582	SAGRES DISCOVERY, INC.
WO	NOVEL COMPOSITIONS AND METHODS FOR CANCER	PCT/US02/41776	SAGRES DISCOVERY, INC.
WO	NOVEL COMPOSITIONS AND METHODS FOR CANCER	PCT/US02/41414	SAGRES DISCOVERY, INC.
WO	NOVEL COMPOSITIONS AND METHODS FOR CANCER	PCT/US03/06146	SAGRES DISCOVERY, INC.
WO	NOVEL COMPOSITIONS AND METHODS FOR CANCER	PCT/US03/06235	SAGRES DISCOVERY, INC.
WO	NOVEL COMPOSITIONS AND METHODS IN CANCER ASSOCIATED WITH ALTERED EXPRESSION OF PRDM11	PCT/US03/08808	SAGRES DISCOVERY, INC.

sd-173861
437786 v1/HN
9DSQ01!.DOC

TRADEMARK
REEL: 002776 FRAME: 0111

COUNTRY	TITLE	APPLICATION NUMBER	OWNER
WO	NOVEL COMPOSITIONS AND METHODS IN CANCER ASSOCIATED WITH ALTERED EXPRESSION OF MCM3AP	PCT/US03/08071	SAGRES DISCOVERY, INC.
WO	NOVEL COMPOSITIONS AND METHODS IN CANCER ASSOCIATED WITH ALTERED EXPRESSION OF TBX21	PCT/US03/08188	SAGRES DISCOVERY, INC.
WO	NOVEL COMPOSITIONS AND METHODS IN CANCER ASSOCIATED WITH ALTERED EXPRESSION OF PRLR	PCT/US03/07470	SAGRES DISCOVERY, INC.
WO	NOVEL COMPOSITIONS AND METHODS IN CANCER ASSOCIATED WITH ALTERED EXPRESSION OFKCNJ9	PCT/US03/07469	SAGRES DISCOVERY, INC.
US	METHODS AND COMPOSITIONS FOR INSERTION MUTATION SCANNING (IMS) OF GENOMES	10/020,508	SAGRES DISCOVERY, INC.
US	NOVEL COMPOSITIONS AND METHODS IN CANCER	10/394,948	SAGRES DISCOVERY, INC.
WO	NOVEL COMPOSITIONS AND METHODS IN CANCER	PCT/US03/08919	SAGRES DISCOVERY, INC.
US	NOVEL COMPOSITIONS AND METHODS IN CANCER	10/322,281	SAGRES DISCOVERY, INC.
US	NOVEL COMPOSITIONS AND METHODS IN CANCER	10/331,053	SAGRES DISCOVERY, INC.
US	NOVEL THERAPEUTIC TARGETS IN CANCER	10/322,696	SAGRES DISCOVERY, INC.
US	NOVEL COMPOSITIONS AND METHODS IN CANCER	10/330,773	SAGRES DISCOVERY, INC.
US	NOVEL THERAPEUTIC TARGETS IN CANCER	10/367,094	SAGRES DISCOVERY, INC.
US	NOVEL THERAPEUTIC TARGETS IN CANCER	10/388,838	SAGRES DISCOVERY, INC.
US	NOVEL THERAPEUTIC TARGETS IN CANCER	10/417,375	SAGRES DISCOVERY, INC.
US	NOVEL THERAPEUTIC TARGETS IN CANCER	10/461,862	SAGRES DISCOVERY, INC.
US	NOVEL THERAPEUTIC TARGETS IN CANCER	10/669,920	SAGRES DISCOVERY, INC.
US	NOVEL THERAPEAUTIC TARGETS IN CANCER	10/663,431	SAGRES DISCOVERY, INC.
US	NOVEL COMPOSITIONS AND METHODS IN CANCER	10/691,209	SAGRES DISCOVERY, INC.

sd-173861
437786 v1/HN
9DSQ011.DOC

TRADEMARK
REEL: 002776 FRAME: 0112

COUNTRY	TITLE	APPLICATION NUMBER	OWNER
US	NOVEL COMPOSITIONS AND METHODS IN CANCER	10/692,382	SAGRES DISCOVERY, INC.
US	NOVEL THERAPEUTIC TARGETS IN CANCER	10/674,575	SAGRES DISCOVERY, INC.
US	NOVEL COMPOSITIONS AND METHODS IN CANCER	10/676,684	SAGRES DISCOVERY, INC.
US	NOVEL THERAPEUTIC TARGETS IN CANCER	10/670,914	SAGRES DISCOVERY, INC.
US	NOVEL COMPOSITIONS AND METHODS IN CANCER ASSOCIATED WITH ALTERED EXPRESSION OF PRDM11	10/105,637	SAGRES DISCOVERY, INC.
US	NOVEL COMPOSITIONS AND METHODS FOR CANCER	10/052,482	SAGRES DISCOVERY, INC.
US	NOVEL COMPOSITIONS AND METHODS IN CANCER ASSOCIATED WITH ALTERED EXPRESSION OF TBX21	10/105,613	SAGRES DISCOVERY, INC.
US	NOVEL COMPOSITIONS AND METHODS IN CANCER ASSOCIATED WITH ALTERED EXPRESSION OF PRLR	10/105,948	SAGRES DISCOVERY, INC.
US	FRATURAL-FORMING ALKYLKETENE DIMERS FOR INTEGRAL MEMBRANE PROTEIN CRYSTAL GROWTH	60/506,125	Duty to Assign
US	RHO ANTIBODY AND TAG TO PURIFY CELL SURFACE PROTEINS	60/506,304	Duty to Assign
US	NOVEL SPLICE VARIANTS OF HUMAN	60/507,682	Duty to Assign

SCHEDULE B
to the Patent and Trademark Security Agreement

U.S. Registered Trademarks of Grantor

REGISTRATION SERIAL NO.	TRADEMARK	JURISDICTION REGISTERED IN	REGISTRATION DATE	STATUS
76267959	Oncogenome	United States	Published 10/1/02	Published Intent to Use
76267958	Oncogenome	United States	Published 10/22/02	Published Intent to Use
76316787	Oncoarray	United States	Published 2/26/02	Published Intent to Use
76335326	Making Sense of the Genome	United States	Misassigned 1/3/02	Misassigned Intent to Use
2627681	Sagres Discovery	United States	10/1/02	Registered
76307745	Oncochip	United States	Published 1/7/03	Published Intent to Use
76226665	Sagres	United States	Published 7/9/02	Published Intent to Use
76358674	Making Sense of the Genome	United States	Filed 1/10/02	Pending
78228632	Oncobank	United States	Filed 3/21/03	Non-final action mailed 9/16/03
2741602	Making Sense of the Oncogenomic	United States	7/29/03	Registered
2694913	GATC	United States	3/11/03	Registered

FAX TRANSMISSION

DATE: January 8, 2004

PTO IDENTIFIER:	Serial Number	76267959
	Word Mark:	Oncogenome

MESSAGE TO:	USPTO PTAS System Assignment Services Division
FAX NUMBER:	(703) 306-5995

FROM:	Morrison & Foerster LLP Bruce D. Grant
PHONE:	(858) 720-7962
Attorney Dkt. #:	555610000001

PAGES (Including Cover Sheet): 26

- CONTENTS:
- | |
|---|
| <ol style="list-style-type: none"> 1. Recordation Form Cover Sheet - Security Agreement - Trademarks (1 page, in duplicate); 2. Attachment A to Recordation Form Cover Sheet - Additional Receiving Parties (1 page) 3. Attachment B to Recordation Form Cover Sheet - Trademarks (1 page) 3. Security Agreement (15 pages); 4. Schedule A to Security Agreement (4 pages); and 5. Schedule B to Security Agreement (1 page). 6. Copy of Notice of Non-recordation of Document (1 page) |
|---|

If your receipt of this transmission is in error, please notify this firm immediately by collect call to (858) 720-7987 and send the original transmission to us by return mail at the address below.

Morrison & Foerster LLP
 3811 Valley Centre, Suite 500, San Diego, California 92130
 Telephone: (858) 720-5100 Facsimile: (858) 720-5125

12/24/2003
700058280

Duplicate Copy
For Fee Processing

Form PTO-1594 (Rev. 03/01) OMB No. 0651-0027 (exp. 5/31/2002) **RECORDATION FORM COVER SHEET TRADEMARKS ONLY** U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):
Sagres Discovery Inc.
 Individual(s) Association
 General Partnership Limited Partnership
 Corporation-State Delaware
 Other:
Additional name(s) of conveying party(ies) attached? Yes No

2. Name and address of receiving party(ies):
Name: Forward Ventures IV, L.P.
Internal Address:
Street Address: 9393 Towne Centre Drive Suite 200
City: San Diego
State: CA Zip: 92121

Individual(s) citizenship:
 Association:
 General Partnership:
 Limited Partnership: Delaware
 Corporation-State:
 Other:
If assignee is not domiciled in the United States, a domestic representative designation is attached: (Designations must be a separate document from assignment) Yes No
Additional name(s) & address(es) attached? See Attachment A Yes No

3. Nature of Conveyance:
 Assignment Merger
 Security Agreement Change of Name
 Other:
Execution Date: December 19, 2003


4. Application Number(s) or Registration Number(s):
A. Trademark Application No.(s):
See Attachment B
Additional numbers attached? Yes No

B. Trademark Registration No.(s):
See Attachment B
Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:
Name: Bruce D. Grant
MORRISON & FOERSTER LLP
Internal Address: Atty. Dkt.: 555610000001
Street Address: 3811 Valley Centre Drive, Suite 500
City: San Diego State: CA Zip: 92130-2332

6. Total Number of applications and registrations involved: 11
7. Total fee (37 CFR 3.41) \$ 290.00
 Enclosed
 Authorized to be charged to Deposit Account
 Authorized to be charged to credit card (Form 2038 enclosed)
8. Deposit account number: 03-195 referencing 555610000001 (Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature:
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.
for Bruce D. Grant Name of Person Signing
 Signature
December 24, 2003 Date
Total number of pages including cover sheet, attachments, and document: 24

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, Assignment Services Division, facsimile no. (703) 306-5995, on the date shown below.

Dated: 12-24-03 Signature:  (Michael Boyd)